Oryzon Genomics S.A. (ORY.MC) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-90.8%

€0.21

vs €2.33 price

Levered DCF

€0.22

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

5.2

Safe zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-88.86×	-24.6×	-36.48×	-32.85×	-30.41×	-54.35×	-34.32×	-70.92×
P/B	2.19×	1.04×	1.5×	1.92×	2×	2.43×	2.4×	1.85×
P/S	0×	12.25×	8.62×	0×	13.42×	19.4×	14.27×	12.31×
EV / EBITDA	-34.19×	-22.71×	-28.07×	-25.35×	-19.1×	-38.25×	-33.88×	-20.92×
Gross margin	0.0%	95.9%	98.3%	0.0%	93.0%	94.5%	95.8%	95.7%
Operating margin	0.0%	-60.1%	-32.1%	0.0%	-66.0%	-45.1%	-37.4%	-43.0%
Net margin	0.0%	-49.8%	-23.6%	0.0%	-44.2%	-35.7%	-35.9%	-17.4%
Current ratio	1.95×	0.75×	0.87×	1.34×	3.76×	5.51×	3.58×	3.42×
Debt / equity	0.11×	0.19×	0.17×	0.24×	0.25×	0.18×	0.22×	0.34×
Interest coverage	-10.55×	-3.6×	-2.4×	-4.91×	-15.39×	-9.15×	-4.97×	-3.65×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-2.5%	-4.2%	-4.1%	-5.8%	-6.6%	-4.5%	-6.0%	-2.6%
Return on invested capital	-2.2%	-2.7%	-2.5%	-3.7%	-5.0%	-3.3%	-5.0%	-1.4%
Return on assets	-1.8%	-3.4%	-3.1%	-4.1%	-4.9%	-3.6%	-4.6%	-1.7%
Free cash flow yield	-1.0%	-14.9%	-12.3%	-11.6%	-10.8%	-7.6%	-9.2%	-9.2%
Earnings yield	-1.1%	-4.1%	-2.7%	-3.0%	-3.3%	-1.8%	-2.5%	-1.4%
Enterprise value	€214.9M	€100.7M	€123.8M	€135.1M	€131.4M	€158.6M	€124.8M	€64.6M
Net debt / EBITDA	2.61×	-2.39×	-0.32×	0.73×	1.61×	6.29×	5.93×	6.09×
Cash conversion cycle (days)	-7,494	-2,493	-5,088	121	-1,328	-1,126	-2,476	-1,779